Thrombosis News and Research

Latest Thrombosis News and Research

Drug-coated stents lower risk of heart attack and death

Heart disease patients 65 and older who receive stents coated with medicine to prevent blockages are more likely to survive and less likely to suffer a heart attack than people fitted with stents not coated with medication, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the American College of Cardiology's National Cardiovascular Data Registry.

30 Mar 2009

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

A new analysis from the JUPITER study shows that CRESTOR (rosuvastatin) 20mg significantly cut the risk of venous thromboembolism (VTE) by 43% (p=0.007) compared to placebo among men and women with low to normal cholesterol levels and elevated high-sensitivity C-reactive protein (hsCRP).

29 Mar 2009

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.

29 Mar 2009

Clinical effectiveness of coronary stents in the elderly

29 Mar 2009

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

Transdermal delivery of estrogen therapy available by prescription "seems not to alter" the risk of venous thromboembolism (VTE), or blood clotting, in postmenopausal patients when compared to oral delivery, a new study suggests.

29 Mar 2009

Family history linked to increased risk of venous thrombosis

Children and siblings of those with venous thrombosis, or blood clots in the veins, appear to have more than double the risk of developing the condition than those without a family history, according to a report in the March 23 issue of Archives of Internal Medicine.

23 Mar 2009

Bioabsorbable stents show promise

A study published online in The Lancet presented two year data for the bioabsorbable everolimus coronary stent.

15 Mar 2009

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Results of a Schering-Plough Corporation Phase II trial of SCH 530348, a novel oral thrombin receptor antagonist (TRA), were published today in The Lancet and demonstrated that the investigational antiplatelet compound met its primary endpoints of safety and tolerability.

12 Mar 2009

Number of cardiovascular risk factors could determine safety of IVIg treatment

New research out of Wake Forest University School of Medicine identifies the presence of cardiovascular risk factors as an indicator of how likely it is that elderly, hospitalized patients who receive intravenous immunoglobulin (IVIg) treatment will have a stroke or heart attack.

5 Mar 2009

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

5 Mar 2009

Blood clots after hip and knee replacements

As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.

26 Feb 2009

European Society of Cardiology reaffirms advice on cardiovascular risks associated with long-haul flights

Following a review by The Lancet of the medical issues associated with commercial air travel, the European Society of Cardiology has reaffirmed its advice about the risks of venous thromboembolism (VTE), whose risk, according to The Lancet, is increased "up to four-fold" by long-haul flight.

24 Feb 2009

Fractures due to osteoporosis in seniors a signal for premature death

An Australian study has found that people over 60 years old who have had a fracture because of reduced bone density, or osteoporosis, face a higher risk of death over the next 5 to 10 years compared to the general population and those who experience additional fractures increase their risk of death further.

3 Feb 2009

Inflammation worsens danger due to atherosclerosis

Current research suggests that inflammation increases the risk of plaque rupture in atherosclerosis.

23 Jan 2009

CSL Behring receives FDA approval of RiaSTAP

CSL Behring announced today that the U.S. Food and Drug Administration (FDA) has granted marketing approval for RiaSTAP(TM), the first and only treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenemia and hypofibrinogenemia.

19 Jan 2009

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Schering-Plough Corp. has announced that the European Medicines Agency (EMEA) has validated (accepted for review) its Marketing Authorization Application (MAA) for corifollitropin alfa, the company's experimental, sustained follicle stimulant (SFS).

1 Jan 2009

Drug eluting stents provide better outcomes that bare metal stents in angioplasty

Patients receiving drug eluting stents (DES) - stents coated with medication to prevent narrowing of the artery - as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ.

18 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Single letter in the human genome points to risk for high cholesterol

Write out every letter in the human genome, one A, C, T or G per millimeter, and the text would be 1,800 miles long, roughly the distance from New York to Colorado.

16 Dec 2008

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Portola Pharmaceuticals has announced that it has initiated patient enrollment in INNOVATE-PCI, a large Phase II clinical trial of PRT060128, the Company's novel P2Y12 ADP receptor antagonist, in patients undergoing non-urgent percutaneous coronary intervention (PCI).

10 Dec 2008

Thrombosis News and Research

Latest Thrombosis News and Research

Drug-coated stents lower risk of heart attack and death

CRESTOR (rosuvastatin) shown to significantly reduce risk of venous thromboembolism

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Clinical effectiveness of coronary stents in the elderly

Transdermal delivery of estrogen therapy may show safety benefits as opposed to oral delivery

Family history linked to increased risk of venous thrombosis

Bioabsorbable stents show promise

Schering-Plough's investigational oral thrombin receptor antagonist meets primary endpoint in a newly published study

Number of cardiovascular risk factors could determine safety of IVIg treatment

Number of cardiovascular risk factors could determine safety of intravenous gammaglobulin treatment

Blood clots after hip and knee replacements

European Society of Cardiology reaffirms advice on cardiovascular risks associated with long-haul flights

Fractures due to osteoporosis in seniors a signal for premature death

Inflammation worsens danger due to atherosclerosis

CSL Behring receives FDA approval of RiaSTAP

Schering-Plough announces European submission of fertility medicine Corifollitropin Alfa

Drug eluting stents provide better outcomes that bare metal stents in angioplasty

Abbott starts trial of 2.25 mm stent system

Single letter in the human genome points to risk for high cholesterol

Portola Pharmaceuticals starts phase 2 trial of P2Y12 ADP receptor antagonist in non-urgent percutaneous coronary intervention

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Thrombosis News and Research

Latest Thrombosis News and Research

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in